You have 9 free searches left this month | for more free features.

Programmed Death-Ligand 1 (PDL1, PD-L1)

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

NSCLC, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1) Trial (MK-2870, Pembrolizumab, Carboplatin)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +4 more
  • MK-2870
  • +2 more
  • (no location specified)
Sep 15, 2023

Acute Lymphoblastic Leukemia in Pediatric Trial in Sohag (flow cytometric immunophynotyping)

Not yet recruiting
  • Acute Lymphoblastic Leukemia in Pediatric
  • flow cytometric immunophynotyping
  • Sohag, Egypt
    Sohag University Hospital
Jun 19, 2022

PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLC

Recruiting
  • Non-small Cell Lung Cancer
  • Monza, Italy
    ASST-Monza Ospedale San Gerardo
Jun 9, 2022

NSCLC Trial in Wuhan (Cadonilimab, Pemetrexed, Carboplatin)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Wuhan, Hubei, China
    Qian Chu
Aug 18, 2023

Esophageal Squamous Cell Carcinoma Trial (Paclitaxel, Irinotecan, Pembrolizumab)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Chuo-ku, Tokyo, Japan
    National Cancer Center Hospital ( Site 3700)
Jan 31, 2023

NSCLC (NSCLC) Trial in Shanghai (Tumor treating fields(EFE-P100), Docetaxel injection)

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • Tumor treating fields(EFE-P100)
  • Docetaxel injection
  • Shanghai, China
    Shanghai Pulmonary Hospital
Dec 21, 2022

Programmed Death Ligand-1 in Nasopharyngeal and Hyypopharyngeal

Not yet recruiting
  • Nasopharyngeal and Hypopharyngeal Carcinoma
  • immunohistochemical
  • Sohag, Egypt
    Sohag University Hospital
Oct 23, 2022

NSCLC Trial in Marietta, Taichung City, Tainan (Sacituzumab Govitecan, Pembrolizumab)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Sacituzumab Govitecan
  • Pembrolizumab
  • Marietta, Georgia
  • +2 more
Jan 27, 2023

Tumor-Infiltrating Lymphocytes and Programmed Cell Death -

Recruiting
  • Breast Cancer
  • +2 more
  • Observational Study
  • Lucknow, Uttar Pradesh, India
    Sanjay Gandhi Postgraduate Institute of Medical Sciences
Feb 11, 2022

Recurrent/Metastatic Gastric Cancer Trial in Seoul (Nivolumab, Paclitaxel)

Completed
  • Recurrent/Metastatic Gastric Cancer
  • Nivolumab, Paclitaxel
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
Sep 9, 2022

NSCLC Trial (pembrolizumab, carboplatin, paclitaxel)

Active, not recruiting
  • Non-small Cell Lung Cancer
  • pembrolizumab
  • +3 more
  • (no location specified)
Aug 18, 2022

Locally Advanced Cervical Cancer Trial in Villejuif (Atezolizumab, Radiotherapy, Cisplatin)

Recruiting
  • Locally Advanced Cervical Cancer
  • Villejuif, Val De Marne, France
    Gustave Roussy
Feb 15, 2022

NSCLC Trial (pembrolizumab, carboplatin, paclitaxel)

Active, not recruiting
  • Non-small Cell Lung Cancer
  • pembrolizumab
  • +3 more
  • (no location specified)
Aug 18, 2022

Lung Cancer Trial in Assiut (Observational Study ( Tissue Biopsy ))

Completed
  • Lung Cancer
  • Observational Study ( Tissue Biopsy )
  • Assiut, Egypt
    Assiut University
Oct 18, 2021

Rectal Cancer Stage, Oesophageal Cancer Trial in Vienna (CRT, SCPRT, CROSS Protocol)

Not yet recruiting
  • Rectal Cancer Stage
  • Oesophageal Cancer
  • CRT
  • +3 more
  • Vienna, Austria
    Medical University of Vienna
Mar 26, 2022

Large B-cell Lymphoma Trial in Groningen (89Zr-atezolizumab PET-imaging)

Recruiting
  • Large B-cell Lymphoma
  • 89Zr-atezolizumab PET-imaging
  • Groningen, Netherlands
    University Medical Center Groningen
Jul 15, 2022

Urothelial Carcinoma Trial in Worldwide (Zilovertamab vedotin)

Recruiting
  • Urothelial Carcinoma
  • Zilovertamab vedotin
  • Cleveland, Ohio
  • +11 more
Jan 25, 2023

Non Small Cell Lung Cancer, Immune Checkpoint Inhibitor, EGFR Exon 21 Mutation Trial in Peking (Pembrolizumab, pemetrexed,

Not yet recruiting
  • Non Small Cell Lung Cancer
  • +2 more
  • Peking, China
    Peking Union Medical College Hospital
Nov 16, 2023

HIPEC Combined With PD1/PDL1 Inhibitor for Gastric Cancer With

Not yet recruiting
  • Gastric Cancer
  • Observational
  • (no location specified)
Dec 13, 2022

Advanced Melanoma Trial in Worldwide (lenvatinib, pembrolizumab)

Active, not recruiting
  • Advanced Melanoma
  • Chandler, Arizona
  • +22 more
Jul 21, 2022

Lichen Planus Trial in Cairo (Skin Biopsy)

Not yet recruiting
  • Lichen Planus
  • Skin Biopsy
  • Cairo, Egypt
    Cairo University
May 14, 2021

Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy Trial in Guangzhou (Toripalimab,

Not yet recruiting
  • Muscle-Invasive Bladder Carcinoma
  • +2 more
  • Guangzhou, Guangdong, China
    Cancer Center, Sun Yat-sen University
Aug 3, 2023

Advanced Solid Tumors Trial in Australia (HLX20)

Completed
  • Advanced Solid Tumors
  • Darlinghurst, New South Wales, Australia
  • +5 more
Jun 1, 2022

SOX2 & PDL1 Expression on Urinary Bladder Carcinoma

Not yet recruiting
  • Urinary Bladder Neoplasm
    • (no location specified)
    Jun 17, 2022

    Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Infiltrating Renal Pelvis and Ureter Urothelial Carcinoma, Stage

    Recruiting
    • Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall
    • +2 more
    • Therapeutic Conventional Surgery
    • +3 more
    • Aurora, Colorado
    • +82 more
    Jan 24, 2023